Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase

Reproductive BioMedicine Online

Volumn 19, Issue 6, 2009, Pages 789-795

  Lainas, T G ^a   Sfontouris, I A ^a   Zorzovilis, I Z ^a   Petsas, G K ^a   Lainas, G T ^a   Alexopoulou, E ^b   Kolibianakis, E M ^c  

^a Eugonia Iatriki Erevna IVF Centre   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Embryo cryopreservation; GnRH antagonist; Luteal phase; Luteolysis; OHSS; PCOS

Indexed keywords

DRUG DERIVATIVE; GANIRELIX; GONADORELIN;

ADULT; ARTICLE; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; HUMAN; LUTEAL PHASE; METHODOLOGY; NEWBORN; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREGNANCY OUTCOME;

ADULT; EMBRYO TRANSFER; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFANT, NEWBORN; INFERTILITY, FEMALE; LUTEAL PHASE; OOCYTE RETRIEVAL; OVARIAN HYPERSTIMULATION SYNDROME; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME;

EID: 77449101078     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.09.021     Document Type: Article

References (32)

1. Aboulghar MA, Mansour RT 2003 Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update 9, 275-289.
2. Aboulghar MA, Mansour RT, Amin YM et al. 2007 A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reproductive BioMedicine Online 15, 271-279.
3. Amarin ZO 2003 Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Human Reproduction 18, 659-664.
4. Asch RH, Ivery G, Goldsman M, Frederick JL et al. 1993 The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction 8, 1015-1020.
5. Asimakopoulos B, Nikolettos N, Nehls B et al. 2006 Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertility and Sterility 86, 636-641.
6. D'Angelo A, Amso NN 2002 Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction 17, 2787-2794.
7. Delvigne A, Rozenberg S 2002a Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 8, 559-577.
8. Delvigne A, Rozenberg S 2002b Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. International Journal of Fertility and Women's Medicine 47, 211-226.
9. Elizur SE, Tulandi T 2008 Drugs in infertility and fetal safety. Fertility and Sterility 89, 1595-1602.
10. Endo T, Honnma H, Hayashi T et al. 2002 Continuation of GnRH agonist administration for 1 week, after HCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction 17, 2548-2551.
11. Fatemi HM, Popovic-Todorovic B, Donoso P et al. 2008 Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reproductive BioMedicine Online 17, 307-311.
12. Fineschi V, Neri M, Di Donato S et al. 2006 An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. International Journal of Legal Medicine 120, 293-299.
13. Garcia-Velasco JA, Quea G, Piro M et al. 2009 Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertility and Sterility 92, 222-225.
14. Griesinger G, von Otte S, Schroer A et al. 2007 Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Human Reproduction 22, 1348-1352.
15. Hughes JN 2002 Ovarian stimulation for assisted reproduction technologies. In: Vayena E, Rowe PJ, Griffin PD, editors Current Practices and Controversies in Assisted Reproduction. Geneva: World Health Organization; 2002. p. 102-125.
16. Kang IS, Kuehl TJ, Siler-Khodr TM 1989 Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertility and Sterility 52, 846-853.
17. Kol S 2004 Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 81, 1-5.
18. Kolibianakis EM, Papanikolaou EG, Tournaye H et al. 2007 Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertility and Sterility 88, 1382-1388.
19. Lainas TG, Sfontouris IA, Zorzovilis IZ et al. 2009 Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reproductive BioMedicine Online 18, 15-20.
20. Lainas TG, Sfontouris IA, Zorzovilis IZ et al. 2007 Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reproductive BioMedicine Online 15, 408-412.
21. Lainas T, Zorzovilis J, Petsas G et al. 2005 In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Human Reproduction 20, 2426-2433.
22. Lainas T, Petsas G, Stavropoulou G et al. 2002 Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertility and Sterility 78, 529-533.
23. Mais V, Kazer RR, Cetel NS et al. 1986 The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. Journal of Clinical Endocrinology and Metabolism 62, 1250-1255.
24. Minaretzis D, Jakubowski M, Mortola JF et al. 1995 Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. Journal of Clinical Endocrinology and Metabolism 80, 430-434.
25. Navot D, Bergh PA, Laufer N 1992 Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 58, 249-261.
26. Porter RN, Smith W, Craft IL et al. 1984 Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 2, 1284-1285.
27. Practice Committee of the American Society for Reproductive Medicine 2004 Ovarian hyperstimulation syndrome. Fertility and Sterility 82, 81-86.
28. Rizk B, Aboulghar M, Smitz J et al. 1997 The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update 3, 255-266.
29. Sher G, Zouves C, Feinman M et al. 1995 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Human Reproduction 10, 3107-3109.
30. Siler-Khodr TM, Kuehl TJ, Vickery BH 1984 Effects of a gonadotropin-releasing hormone antagonist on hormonal levels in the pregnant baboon and on fetal outcome. Fertility and Sterility 41, 448-454.
31. Tavaniotou A, Devroey P 2006 Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reproductive BioMedicine Online 13, 326-330.
32. Taylor PD, Hillier SG, Fraser HM 2004 Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. Journal of Endocrinology 183, 1-17.